Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03796962 · ClinicalTrials.gov registry record · Phase 2
A Study to Evaluate XEN1101 as Adjunctive Therapy in Focal Epilepsy
A Phase 2 study of Focal Epilepsy, sponsored by Xenon Pharmaceuticals.
- Active
- Registry status
- Phase 2
- Development phase
- 325
- Enrollment target
- 20
- Study locations
NCT03796962: Active Phase 2 study of Focal Epilepsy, sponsored by Xenon Pharmaceuticals.
NCT03796962 is a Phase 2 study of Focal Epilepsy that is active but no longer recruiting, run by Xenon Pharmaceuticals. The registered enrollment target is 325 participants, above the 132-participant average among 8 other Focal Epilepsy trials with a reported enrollment target (146% higher). The trial reports 20 study locations across 10 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03796962, a Phase 2 study of Focal Epilepsy, is active but no longer recruiting, sponsored by Xenon Pharmaceuticals.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 325 participants
- Enrollment target
- 20
- Study locations
Study Summary
The XEN1101 Phase 2 clinical trial is a randomized, double-blind, placebo-controlled study that will evaluate the clinical efficacy, safety and tolerability of increasing doses of XEN1101 administered as adjunctive treatment in adult patients diagnosed with focal epilepsy, followed by an optional open-label extension (OLE).
Primary Outcome
Median percent change in monthly (28 days) focal seizure frequency from baseline to DBP for XEN1101 versus placebo
Conditions Studied
Interventions
- DRUG XEN1101
Study Locations (20)
Florida
- University of Florida Jacksonville - Jacksonville
- Mayo Clinic Florida - Jacksonville
- Visionary Investigators Network - Miami
- Don Clinical Research Center - Miami
- The Neurology Research Group, LLC. - Miami
- Research Institute of Orlando, LLC - Orlando
- Medsol Clinical Research Center - Port Charlotte
- Tallahassee Neurological Clinic - Tallahassee
- University of South Florida - Tampa
Alabama
- University of Alabama at Birmingham - Birmingham
- Strada Patient Care Center - Mobile
California
- Altman Clinical Translational Research Institute (ACTRI) - La Jolla
- California Pacific Medical Center (CPMC) - Sutter Pacific Epilepsy Program - San Francisco
Arizona
- Xenoscience, Inc. - Phoenix
Arkansas
- Clinical Trials, Inc. - Little Rock
Colorado
- University of Colorado Hospital Anschutz Outpatient Pavilion - Aurora
Georgia
- Georgia Neurology and Sleep Medicine Associate - Suwanee
Hawaii
- Hawaii Pacific Neuroscience - Honolulu
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 325 participants |
| Start Date | 2019-01-30 |
| Est. Completion | 2028-10 |
| Phase | Phase 2 |
What the registry record for NCT03796962 still lists
NCT03796962 is an interventional study that assigns participants to a tested intervention. The registered 325 participants enrollment target is mid-sized for trials with a published cap, above the 132-participant average among 8 other Focal Epilepsy trials with a reported enrollment target (146% higher).
The record links to 1 condition, with Focal Epilepsy appearing as the primary indexed condition, and to 1 intervention - of which XEN1101 is the first listed.
NCT03796962 names 20 study sites across 10 states, led by Florida, Alabama, California.
Frequently Asked Questions
What is clinical trial NCT03796962 about?
NCT03796962 is a clinical study titled "A Study to Evaluate XEN1101 as Adjunctive Therapy in Focal Epilepsy". The XEN1101 Phase 2 clinical trial is a randomized, double-blind, placebo-controlled study that will evaluate the clinical efficacy, safety and tolerability of increasing doses of XEN1101 administered as adjunctive treatment in adult patients diagnosed with focal epilepsy, followed by an optional op...
What is the current status of trial NCT03796962?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 325 participants. The study started on 2019-01-30. Estimated completion is 2028-10.
What conditions does trial NCT03796962 study?
This clinical trial studies the following conditions: Focal Epilepsy.
What interventions are being tested in trial NCT03796962?
The interventions under investigation include: XEN1101 (DRUG).
Who is sponsoring clinical trial NCT03796962?
This trial is sponsored by Xenon Pharmaceuticals, which has 13 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03796962 being conducted?
This trial has 20 study locations across Alabama, Arizona, Arkansas, California, Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Focal Epilepsy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03796962's enrollment target sits among peer trials
325 3rd of 8 higher than 6 of 8 other Focal Epilepsy trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Focal Epilepsy trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Study to Determine if BHV-7000 is Effective and Safe in Adults With Refractory Focal Onset Epilepsy
RECRUITING · Phase 2
-
A Long-term Study of the Safety and Effectiveness of RAP-219 in Adults With Focal Onset Seizures
RECRUITING · Phase 2
-
A Study to Determine if BHV-7000 is Effective and Safe in Adults With Refractory Focal Onset Epilepsy
RECRUITING · Phase 2
-
Diffusion MRI Methods to Minimize Postoperative Deficits in Pediatric Epilepsy Surgery
RECRUITING · NA
-
Breathing Rescue for SUDEP Prevention
RECRUITING · NA
-
Study of Transcranial Direct Current Stimulation to Treat Epilepsy
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02543983 · 325 participants · Phase 2
Neurobiology of Suicide
- NCT03016819 · 325 participants · Phase 3
Phase III Trial of Anlotinib, Catequentinib in Advanced Alveolar Soft Part Sarcoma, Leiomyosarcoma, Synovial Sarcoma (APROMISS)
- NCT03288207 · 325 participants · NA
Tailoring Mobile Health Technology to Reduce Obesity and Improve Cardiovascular Health in Resource-Limited Neighborhood Environments
- NCT04986657 · 325 participants · NA
Whole Genome Sequencing (ChromoSeq) as an Adjunct to Conventional Genomic Profiling in AML and MDS
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI